Pharmaceuticals
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
Novocure Could Climb Even Further; Here's Where to Buy
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal
Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.
New Targets for Merck Stock as Charts Point Higher
Investors and traders should approach MRK from the long side.
Bulls Walk the Market Up Slowly, but Keep One Eye on Fed
I'm inclined to add to Disney on today's weakness.
Don't Jump Into Charles River Labs Just Yet
CRL could weaken further in upcoming weeks for a better buying opportunity.
IPO Gives Chinese Couple a 'Hansoh' Sum
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results
The company is testing its hematologic malignancies treatment.
Kura Oncology Soars After Lymphoma Treatment Test Results
Kura Oncology climbs after the clinical-stage biopharmaceutical company says a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results.
Savara Plunges After Lung Disease Drug Fails Phase 3 Trial
The stock falls below $3 after closing Wednesday's session at $10.57.